Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for treating type 2 diabetes mellitus. Whilst not specifically indicated for lipid management, emerging clinical evidence suggests that Mounjaro does lower triglycerides in many patients as a secondary metabolic benefit. This effect appears to result from weight loss, improved insulin sensitivity, and direct metabolic actions. For individuals with type 2 diabetes and elevated triglycerides, Mounjaro may offer complementary benefits alongside established lipid-lowering therapies. However, treatment decisions should be based on its licensed indication, with statins remaining first-line for dyslipidaemia management in diabetes.

What Is Mounjaro and How Does It Work?

Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus. It is administered as a once-weekly subcutaneous injection and belongs to a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.

The mechanism of action of Mounjaro involves activating both GIP and GLP-1 receptors, which are naturally occurring incretin hormones that play crucial roles in glucose homeostasis and appetite regulation. By stimulating these receptors, tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite. This dual agonism is thought to provide synergistic benefits beyond those seen with GLP-1 receptor agonists alone.

In clinical trials, Mounjaro has demonstrated substantial reductions in HbA1c (a marker of long-term blood glucose control) and significant weight loss in people with type 2 diabetes. These metabolic improvements extend beyond glycaemic control, with emerging evidence suggesting favourable effects on various cardiovascular risk factors, including blood pressure and lipid profiles. The MHRA-approved indication reflects its role as an adjunct to diet and exercise for adults with type 2 diabetes, and it is typically prescribed when other glucose-lowering therapies have not achieved adequate control.

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation, which are usually mild to moderate and tend to diminish over time. Patients should be counselled on gradual dose escalation to minimise these effects.

Important safety information: When used with sulfonylureas or insulin, there is an increased risk of hypoglycaemia, and dose reduction of these medications may be needed. Women using oral contraceptives should use additional contraception for 4 weeks after starting Mounjaro and after each dose increase. There is also a risk of gallbladder disease (cholelithiasis, cholecystitis); patients should be advised to report symptoms such as right upper abdominal pain, fever or jaundice. Mounjaro is not recommended during pregnancy or breastfeeding.

Who Should Consider Mounjaro for Triglyceride Management?

Mounjaro is not currently licensed specifically for the treatment of hypertriglyceridaemia (elevated triglycerides), and it should not be prescribed solely for lipid management. However, individuals with type 2 diabetes who also have elevated triglyceride levels may experience secondary benefits on their lipid profile when treated with tirzepatide for its approved indication.

Patients who may benefit include those with:

• Type 2 diabetes with inadequate glycaemic control and coexisting dyslipidaemia (abnormal lipid levels)

• Metabolic syndrome, which often includes elevated triglycerides

• Cardiovascular risk factors where comprehensive metabolic improvement is desirable

It is important to note that NICE guidance recommends a holistic approach to cardiovascular risk reduction in people with type 2 diabetes. This includes lifestyle modification (dietary changes, increased physical activity, smoking cessation, and alcohol moderation), optimisation of glycaemic control, blood pressure management, and lipid-lowering therapy where indicated. Statins remain the first-line pharmacological treatment for dyslipidaemia in most patients with diabetes, as they have robust evidence for reducing cardiovascular events.

Mounjaro should be considered as part of an individualised treatment plan developed in consultation with a GP or specialist. It is not a replacement for established lipid-lowering therapies but may offer complementary metabolic benefits. Patients with severe hypertriglyceridaemia (triglycerides >10 mmol/L) require urgent specialist assessment due to the risk of acute pancreatitis, and fibrates may be more appropriate initial interventions in such cases, as guided by specialist advice.

Special precautions: Mounjaro should be used with caution in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Caution is also advised in patients with a history of pancreatitis. If pancreatitis is suspected (severe abdominal pain, possibly with nausea and vomiting), stop taking Mounjaro and seek urgent medical attention by calling 999 or going to A&E.

Monitoring Your Triglycerides While Taking Mounjaro

If you are prescribed Mounjaro and have elevated triglycerides or other lipid abnormalities, regular monitoring is essential to assess treatment response and guide ongoing management. Your healthcare team will typically arrange blood tests to measure your lipid profile, which includes total cholesterol, LDL-cholesterol (often called 'bad' cholesterol), HDL-cholesterol ('good' cholesterol), and triglycerides.

Baseline assessment should be performed before starting Mounjaro, including a full lipid profile, HbA1c, renal function, and liver function tests. This provides a reference point for evaluating changes over time. According to NICE guidance (NG28), lipid profiles should be checked annually in people with type 2 diabetes, or more frequently if lipid-lowering therapy is initiated or adjusted.

While taking Mounjaro, your GP or diabetes specialist may recommend:

• Repeat lipid profiles after starting treatment to assess metabolic response

• Ongoing annual monitoring as part of routine diabetes care

• More frequent testing if you have significantly elevated triglycerides or are on additional lipid-lowering medications

In the UK, non-fasting lipid profiles are standard practice for most patients. Fasting samples are only required if specifically requested by your doctor or if your triglyceride levels are very high (for example >10 mmol/L). If fasting is needed, follow your local laboratory's instructions, which typically involve not eating for 8-12 hours before the test (water is permitted). It's also advisable to avoid heavy alcohol consumption before the test as this can affect results.

Patient safety advice: If you experience severe abdominal pain while taking Mounjaro, particularly if accompanied by nausea and vomiting, stop taking the medication, call 999 or go to A&E immediately, as this may indicate pancreatitis. Very high triglyceride levels are a risk factor for this serious condition. Additionally, report any unexplained weight loss, persistent gastrointestinal symptoms, or signs of dehydration to your healthcare provider. Suspected side effects can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Does Mounjaro Lower Triglycerides? Clinical Evidence

Emerging clinical evidence suggests that Mounjaro does lower triglycerides in many patients, although this effect is considered a secondary metabolic benefit rather than the primary therapeutic target. Data from the SURPASS clinical trial programme, which evaluated tirzepatide in people with type 2 diabetes, consistently demonstrated improvements in lipid parameters alongside reductions in HbA1c and body weight.

In the SURPASS-2 trial published in the New England Journal of Medicine, participants treated with tirzepatide (5 mg, 10 mg, or 15 mg weekly) experienced reductions in fasting triglycerides from baseline over 40 weeks, with greater reductions generally seen at higher doses. The European Medicines Agency's assessment report notes improvements in triglyceride levels across the SURPASS programme, with the magnitude of triglyceride reduction generally correlating with the degree of weight loss achieved.

The mechanisms underlying triglyceride reduction with Mounjaro are multifactorial and likely include:

• Weight loss: Reduction in adipose tissue decreases hepatic very-low-density lipoprotein (VLDL) production, the primary carrier of triglycerides in the blood

• Improved insulin sensitivity: Enhanced insulin action reduces hepatic lipogenesis (fat synthesis) and increases lipoprotein lipase activity, promoting triglyceride clearance

• Reduced caloric intake: Appetite suppression leads to decreased dietary fat consumption

• Direct metabolic effects: GIP and GLP-1 receptor activation may influence lipid metabolism through pathways that are not yet fully understood

It is important to emphasise that there is no official indication for Mounjaro as a lipid-lowering agent, and treatment decisions should be based on its licensed use for type 2 diabetes. The triglyceride-lowering effect, while clinically meaningful for many patients, is variable and should not replace evidence-based lipid management strategies when specifically indicated. Patients with persistent hypertriglyceridaemia despite lifestyle modification and glucose control may require additional lipid-lowering therapy as recommended by NICE guidance NG238, with statins remaining the first-line approach for most patients.

Further cardiovascular outcome trials, including SURPASS-CVOT, are ongoing to determine whether the metabolic improvements seen with tirzepatide, including effects on triglycerides, translate into reduced rates of heart attack, stroke, and cardiovascular death.

Frequently Asked Questions